Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved omaveloxolone (Skyclarys), the first treatment for patients aged 16 and over, in the UK for a rare neurodegenerative ...

Stemchymal® is an allogeneic adipose-derived mesenchymal stem cell (MSC) therapy developed for spinocerebellar ataxia (SCA), a rare neurodegenerative disease that is currently incurable.

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first treatment for patients aged 16 years and older with the rare ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Installation is included in the price and can be done in a matter of days. Financing options are available on Midline and Classic pool models. The company offers free site inspections and ...

Patients with a central defect are best treated by anterior colporrhaphy, which reapproximates the pubocervical fascia in the midline. Although a variety of techniques exist, we place multiple ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich’s ataxia in ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment for patients aged 16 and over, in the UK for a rare neurodegenerative ...

As with all products, we will keep its safety under close review. The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 April, approved omaveloxolone (Skyclarys), the first ...